On the decision to de-list the Korea Exchange on the 14th, Keangnam Pharmaceutical Co. officially announced on the 17th that it will do its best to make a decision on holding the store and resuming the transaction.
"It is regrettable and deeply regrettable that the Korea Exchange's Corporate Review Committee decided to delist from the listing," said Keangnam Pharmaceutical Co. in an article posted on its website on the same day.
"Before the final screening by the KOSDAQ Market Committee, which will decide whether to abolish the listing or not, we will be more active in explaining the company's efforts to improve its management and make necessary preparations," said Keangnam Pharmaceutical Co.
Gyeongnam Pharmaceutical Co. explained that 사설토토 it had been decided as a subject of a real audit of listing eligibility as a result of accounting violation since February 28, 2018, and has continuously been paying back its loan to secure financial soundness, reducing its loan of about 11.1 billion won to about 5.5 billion won as of the end of last year.
"In the business sector, sales are expected to increase at around 5% compared to last year despite difficulties both at home and abroad by entering Chinese markets, releasing various new products by distribution channels, and improving internal efficiency," he added.
"The company changed its largest shareholders by attracting investment cooperatives run by the New Technology Business Association as strategic investors, and, along with the largest shareholder MilestoneKN Fund, it attracted additional bonuses and established a professional management system to secure financial soundness under the principle of separation of ownership and management."
Gyeongnam Pharmaceutical Co. emphasized that if all its executives and employees do their best to make a decision to maintain the market and resume business, the KOSDAQ Market Committee will make a wise and fair decision, which will be in line with the understanding of some 5,000 shareholders and the wishes of 230 employees.
"All members of Gyeongnam Pharmaceutical Co. will do their best to keep up with the expectations of shareholders who trusted the company and customers who love Gyeongnam Pharmaceutical Co."